Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Real Time Genomics Appoints Steve Lombardi as CEO

Published: Thursday, April 26, 2012
Last Updated: Thursday, April 26, 2012
Bookmark and Share
Genomics industry veteran will drive commercialization of the company’s highly scalable core technology for next generation genomic analysis.

Real Time Genomics, Inc. announced the appointment of genomics industry veteran Steve Lombardi as the company’s President and Chief Executive Officer. Lombardi will lead the company as it commercializes its highly scalable, patented, core technology for use in next generation genomic analysis.

“We are pleased to have someone of Steve’s caliber join RTG as CEO,” stated Mark Silverman, Partner at Catamount Ventures, the private company’s lead venture investor. “His knowledge of the genomics marketplace and extensive industry relationships make him a perfect fit for the company. With Steve on board, we see RTG making a substantial impact in accelerating customers’ ability to utilize genomic content in research and in the clinic.”

Lombardi has 30+ years of commercial biotechnology experience. He has led the commercialization of key technologies that have defined modern molecular biology, and has been responsible for the largest and fastest growing product lines in the life science tools industry. From 2006 to 2010, Lombardi was President and then CEO of Helicos BioSciences. From 2002 to 2006, he was a senior executive at Affymetrix running corporate development and business management. From 1986 to 2002, Lombardi held increasingly responsible positions at Applied Biosystems in product, sales and business management, including general management of their DNA sequencing business, during which time annual revenues in his division grew from $10M to ~$800M.

“Bioinformatics and computational biology are the next big frontier in genomics,” said Steve Lombardi. “Advances in tools and applications that allow scientists to interpret and extract value from NGS data have driven a renaissance in sequence-based genetic analysis. My goal is to build RTG into the market leader of next generation genomic analysis based on the company’s unique technology. I am excited about working with a great team to make RTG a valuable contributor to the advancement of genomic science and a leading company in the genomics industry.”

The Real Time Genomics mission is to further enable the genomics revolution by providing the best genomics analysis software in the industry. The first step in fulfilling that mission is to apply its patented core technology to solve the bottleneck that currently limits large scale genomic analysis. Today, RTG software addresses some of the most demanding applications of high-throughput sequence data, like providing comprehensive variant detection and metagenomic analysis pipelines. As an example, a complete RTG solution for high-throughput metagenomics was developed in collaboration with The Genome Institute at Washington University in St. Louis for use in the Human Microbiome Project.

“The appointment of Steve Lombardi as CEO is a significant enhancement for Real Time Genomics,” said George Weinstock, Associate Director, The Genome Institute and Professor of Genetics at Washington University in St. Louis. “His industry experience and relationships are invaluable to an emerging company like RTG that has developed a great base of technology. Steve’s industry intuition complements the company’s existing technical know-how and provides an important new ingredient for maturing their technology into world class genomics products.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

RTG and JCVI Embark on Strategic Research Initiative
Long-term collaboration to understand de novo mutations for stem cell progression study and deliver validated, gold-standard datasets.
Friday, May 03, 2013
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!